Hend El-Sherbini loses $19.5 million from IDH shares

Key Points

• Hend El-Sherbini’s IDH stake plunges $19.5 million as stock drops 26% despite company posting record revenue and profit growth in 2024. 
• IDH reports 39% revenue surge to $111.9 million, driven by more tests and patient visits across its five-country diagnostic network. 
• Investor confidence wanes as IDH stock falls 22.7% year-to-date, erasing millions in value for shareholders amid emerging market concerns.

Egyptian businesswoman Hend El-Sherbini, one of the country’s wealthiest entrepreneurs, has experienced a significant financial setback as the value of her holdings in Integrated Diagnostics Holdings (IDH) has dropped by over $19 million in recent months. This is attributed to a sustained decline in the company’s share price on the London Stock Exchange following its voluntary delisting from the Egyptian Exchange (EGX) in 2024. 

El-Sherbini, who serves as CEO of IDH, is a key figure in the company’s rise as a leading diagnostic service provider in the Middle East and North Africa (MENA) region. Her stake in the company, which amounts to 27.94 percent (equivalent to 162,445,383 shares), has now fallen by $19.49 million due to the downturn in IDH’s stock price.

IDH records 39% growth in revenue, reaches $111.9 million

IDH is one of the largest consumer healthcare groups in MENA, offering over 3,000 diagnostic tests across its network of 628 laboratories spanning five countries. The company remains Egypt’s largest diagnostic service provider, with a strong reputation for delivering high-quality healthcare services. 

In its most recent financial report, IDH posted a revenue of EGP5.72 billion ($111.88 million) for fiscal year 2024, marking a 38.73 percent increase from EGP4.12 billion ($80.65 million) in 2023. The company also reported a net profit of EGP1 billion ($19.72 million) for FY 2024, reflecting a remarkable 115.38 percent growth from EGP468 million ($9.15 million) in 2023. The surge in both revenue and profit was driven by a 9 percent year-on-year increase in testing volume and a 5 percent rise in patient visits.

IDH stock plunges 26% despite strong financial performance

Despite these positive financial results, IDH’s stock has taken a significant hit in the past three months. The company’s share price on the London Stock Exchange has plunged by 26.09 percent, from $0.46 on Jan. 6 to $0.34 at the time of writing, reducing IDH’s market value to $204 million. This decline has impacted major shareholders, including El-Sherbini, whose stake in the company has dropped from $74.72 million to $55.23 million over the period. 

IDH’s stock is also down 22.73 percent year-to-date, reflecting broader concerns among investors about the performance of emerging market stocks, particularly in the healthcare sector. A $100,000 investment in IDH shares at the beginning of the year would now be worth just $77,270. Hend El-Sherbini remains one of Egypt’s most influential business figures. She continues to hold a significant position at IDH, reinforcing her status as one of the country’s top investors and a prominent player in the MENA region’s healthcare landscape.